Beyond the Graft: Recurrence of Interstitial Lung Diseases Post Transplant

Overview

Journal J Clin Med

Specialty General Medicine

Date 2025 Feb 26

PMID 40004625

Authors

Prince Ntiamoah

Atul C Mehta

Affiliations

Soon will be listed here.

Abstract

Interstitial lung diseases (ILDs) represent a heterogenous group of lung disorders marked by inflammation and/or fibrosis of the lung parenchyma, often leading to progressive shortness of breath and end-stage respiratory failure. In the U.S., ILDs affect approximately 650,000 individuals and cause approximately 25,000-30,000 deaths annually. Lung transplantation (LTx) offers definitive treatment for advanced ILD, with improved survival attributed to advancements in immunosuppression, organ preservation, surgical techniques, and postoperative care. However, disease recurrence in transplanted lungs remains a significant concern. Understanding the risk factors and mechanisms underlying recurrence is critical for refining recipient selection and improving outcomes. This review examines ILD recurrence post LTx and its implications for lung transplantation success.

References

Kapse B, Budev M, Singer J, Greenland J . Immune aging: biological mechanisms, clinical symptoms, and management in lung transplant recipients. Front Transplant. 2024; 3:1356948. PMC: 11235310. DOI: 10.3389/frtra.2024.1356948. View

Yousem S . Alveolar lipoproteinosis in lung allograft recipients. Hum Pathol. 1998; 28(12):1383-6. DOI: 10.1016/s0046-8177(97)90228-8. View

Divithotawela C, Apte S, Tan M, De Silva T, Chambers D . Pulmonary alveolar proteinosis after lung transplantation. Respirol Case Rep. 2020; 8(5):e00566. PMC: 7199162. DOI: 10.1002/rcr2.566. View

Faust H, Golden J, Rajalingam R, Wang A, Green G, Hays S . Short lung transplant donor telomere length is associated with decreased CLAD-free survival. Thorax. 2017; 72(11):1052-1054. PMC: 6550329. DOI: 10.1136/thoraxjnl-2016-209897. View

Pacheco Y, Lim C, Weichhart T, Valeyre D, Bentaher A, Calender A . Sarcoidosis and the mTOR, Rac1, and Autophagy Triad. Trends Immunol. 2020; 41(4):286-299. DOI: 10.1016/j.it.2020.01.007. View

Everaerts S, Lammertyn E, Martens D, De Sadeleer L, Maes K, van Batenburg A . The aging lung: tissue telomere shortening in health and disease. Respir Res. 2018; 19(1):95. PMC: 5948770. DOI: 10.1186/s12931-018-0794-z. View

Kazerooni E, Jackson C, Cascade P . Sarcoidosis: recurrence of primary disease in transplanted lungs. Radiology. 1994; 192(2):461-4. DOI: 10.1148/radiology.192.2.8029415. View

Pigula F, Griffith B, Zenati M, Dauber J, Yousem S, Keenan R . Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg. 1998; 64(6):1630-4. DOI: 10.1016/s0003-4975(97)00930-2. View

Ionescu D, Hunt J, Lomago D, Yousem S . Recurrent sarcoidosis in lung transplant allografts: granulomas are of recipient origin. Diagn Mol Pathol. 2005; 14(3):140-5. DOI: 10.1097/01.pas.0000176765.26047.6f. View

10.

Linke M, Pham H, Katholnig K, Schnoller T, Miller A, Demel F . Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017; 18(3):293-302. PMC: 5321578. DOI: 10.1038/ni.3655. View

11.

Milman N, Hoffmann A . Childhood sarcoidosis: long-term follow-up. Eur Respir J. 2007; 31(3):592-8. DOI: 10.1183/09031936.00011507. View

12.

Chambers D, Cherikh W, Harhay M, Hayes Jr D, Hsich E, Khush K . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38(10):1042-1055. PMC: 6816340. DOI: 10.1016/j.healun.2019.08.001. View

13.

Schultz H, Andersen C, Steinbruuchel D, Perch M, Carlsen J, Iversen M . Recurrence of sarcoid granulomas in lung transplant recipients is common and does not affect overall survival. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(2):149-53. View

14.

Saini D, Weber J, Ramachandran S, Phelan D, Tiriveedhi V, Liu M . Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant. 2011; 30(6):624-31. PMC: 3091959. DOI: 10.1016/j.healun.2011.01.708. View

15.

Dauriat G, Mal H, Thabut G, Mornex J, Bertocchi M, Tronc F . Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis. Transplantation. 2006; 81(5):746-50. DOI: 10.1097/01.tp.0000200304.64613.af. View

16.

Nine J, Yousem S, Paradis I, Keenan R, Griffith B . Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant. 1994; 13(4):714-9. View

17.

Martel S, Carre P, Carrera G, Pipy B, Leophonte P . Tumour necrosis factor-alpha gene expression by alveolar macrophages in human lung allograft recipient with recurrence of sarcoidosis. Toulouse Lung Transplantation Group. Eur Respir J. 1996; 9(5):1087-9. DOI: 10.1183/09031936.96.09051087. View

18.

Du E, Yung G, Le D, Masliah E, Yi E, Friedman P . Severe alveolar proteinosis following chemotherapy for acute myeloid leukemia in a lung allograft recipient. J Thorac Imaging. 2001; 16(4):307-9. DOI: 10.1097/00005382-200110000-00014. View

19.

Warrior K, Dilling D . Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant. 2022; 42(1):40-52. DOI: 10.1016/j.healun.2022.09.021. View

20.

Benden C, Rea F, Behr J, Corris P, Reynaud-Gaubert M, Stern M . Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant. 2009; 28(1):1-7. DOI: 10.1016/j.healun.2008.09.014. View